Glutathione
Endogenous tripeptide antioxidant (glutamate-cysteine-glycine). No FDA-approved glutathione drug product in the US; sold as a supplement; injectable products for skin lightening have safety alerts.
60-Second Scientific Briefing
Glutathione is a natural tripeptide (glutamate, cysteine, glycine) that the body makes as a main cellular antioxidant. There is no FDA-approved glutathione drug product in the US; it is sold as a supplement. For skin lightening, small randomised trials of oral and topical glutathione reported modest, localised reductions in melanin, and systematic reviews call the evidence inconclusive or moderate. A 2024 systematic review advises against intravenous glutathione for lightening because of lack of efficacy and side effects, and US authorities reported illnesses and recalls linked to contaminated compounded injections.
What is Glutathione?
Pharmacological Classification & Molecular IdentityGlutathione is a tripeptide (glutamate-cysteine-glycine) made by the body; it is a major cellular antioxidant with anti-melanogenic properties, which led to its use as a skin-lightening agent. [1] Int J Dermatol, 2024 ↗
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingReceptor Selectivity: It acts as an antioxidant and is thought to shift pigment production away from dark eumelanin; it does not act through a specific receptor. Oral absorption and bioavailability are limited. [1] J Dermatolog Treat, 2012 ↗
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsThere is no FDA-approved glutathione drug product in the United States (CDC). It is sold as a dietary supplement. In 2026, US authorities reported more than 25 illnesses in at least four states and pharmacy recalls of compounded injectable glutathione with high endotoxin levels. [1] U.S. Centers for Disease Control and Prevention, 2026 ↗
Glutathione is not approved for commercial sale, prescription therapy, or compounded medication distribution. It exists strictly within authorized scientific and clinical research frameworks.
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesOral RCT (J Dermatolog Treat 2012): 60 healthy medical students, glutathione or placebo for 4 weeks; melanin indices fell at all six sites, significantly more than placebo at two sites (face and sun-exposed forearm). Systematic review 2019 (4 studies): a trend to lightening in sun-exposed skin, with evidence called inconclusive. Systematic review 2024: five oral RCTs and one open study showed reductions in the melanin index vs placebo; topical 0.5% was more effective than 0.1% and placebo; only one placebo-controlled intravenous study (6/16 vs 3/16 responders, P=0.054); risk of bias was mixed and effects were unsustainable. [1] Int J Dermatol, 2024 ↗ [2] J Cosmet Dermatol, 2019 ↗ [3] J Dermatolog Treat, 2012 ↗
Clinical Evidence
Oral RCT (J Dermatolog Treat 2012): 60 healthy medical students, glutathione or placebo for 4 weeks; melanin indices fell at all six sites, significantly more than placebo at two sites (face and sun-exposed forearm). Systematic review 2019 (4 studies): a trend to lightening in sun-exposed skin, with evidence called inconclusive. Systematic review 2024: five oral RCTs and one open study showed reductions in the melanin index vs placebo; topical 0.5% was more effective than 0.1% and placebo; only one placebo-controlled intravenous study (6/16 vs 3/16 responders, P=0.054); risk of bias was mixed and effects were unsustainable.
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesOral and topical glutathione were well tolerated in the trials, with some non-serious adverse events reported. The 2024 systematic review considers intravenous glutathione contraindicated for lightening because of lack of efficacy and side effects. In 2026 the CDC reported illnesses linked to contaminated compounded injectable glutathione. [1] U.S. Centers for Disease Control and Prevention, 2026 ↗ [2] Int J Dermatol, 2024 ↗
Long-term safety of oral use for lightening has not been established, any lightening effect appears unsustainable after stopping, and the quality of injectable products sold outside regulated pharmacies is uncertain. [1] Int J Dermatol, 2024 ↗ [2] J Dermatolog Treat, 2012 ↗
Dose Approval Status
Commercial Dosing Status and Policy DirectivesNo drug dose is approved. Supplement amounts used in the studies are described in the linked papers; they are not a recommendation. There is no approved injectable glutathione product in the US. [1] U.S. Centers for Disease Control and Prevention, 2026 ↗
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- Glutathione is a tripeptide (glutamate-cysteine-glycine) made by the body; it is a major cellular antioxidant with anti-melanogenic properties, which led to its use as a skin-lightening agent.
- Targets & Selectivity: It acts as an antioxidant and is thought to shift pigment production away from dark eumelanin; it does not act through a specific receptor. Oral absorption and bioavailability are limited.
- Oral RCT (J Dermatolog Treat 2012): 60 healthy medical students, glutathione or placebo for 4 weeks; melanin indices fell at all six sites, significantly more than placebo at two sites (face and sun-exposed forearm). Systematic review 2019 (4 studies): a trend to lightening in sun-exposed skin, with evidence called inconclusive. Systematic review 2024: five oral RCTs and one open study showed reductions in the melanin index vs placebo; topical 0.5% was more effective than 0.1% and placebo; only one placebo-controlled intravenous study (6/16 vs 3/16 responders, P=0.054); risk of bias was mixed and effects were unsustainable.
- Safety considerations: Oral and topical glutathione were well tolerated in the trials, with some non-serious adverse events reported. The 2024 systematic review considers intravenous glutathione contraindicated for lightening because of lack of efficacy and side effects. In 2026 the CDC reported illnesses linked to contaminated compounded injectable glutathione.
? Unknown / Under Ongoing Investigation
- Long-term safety of oral use for lightening has not been established, any lightening effect appears unsustainable after stopping, and the quality of injectable products sold outside regulated pharmacies is uncertain.
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keysGlutathione is a natural tripeptide antioxidant made by the body. It is sold as a supplement and widely used for skin lightening; there is no FDA-approved glutathione drug.
- Glutathione as a skin-lightening agent and in melasma: a systematic review (Int J Dermatol, 2024-10-23)
- The clinical effect of glutathione on skin color and other related skin conditions: a systematic review (J Cosmet Dermatol, 2019-06-01)
It is a cellular antioxidant and is thought to shift pigment production away from dark eumelanin. It has no specific receptor, and oral absorption is limited.
- Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study (J Dermatolog Treat, 2012-04-01)
No. There is no FDA-approved glutathione drug product in the US; it is sold as a supplement. US authorities reported illnesses and recalls linked to contaminated compounded injections in 2026.
- Adverse events linked to compounded injectable glutathione: current situation (U.S. Centers for Disease Control and Prevention, 2026-09-11)
Small randomised trials of oral and topical glutathione showed modest, localised reductions in melanin. Systematic reviews call the evidence inconclusive (2019) or moderate but unsustainable (2024); evidence for intravenous use is minimal.
J Dermatolog Treat 2012: 60 healthy medical students in Thailand received oral glutathione or placebo for 4 weeks; melanin indices fell at all six sites with glutathione and significantly more than placebo at the right face and sun-exposed left forearm; both were well tolerated, and the authors noted long-term safety was not established. J Cosmet Dermatol 2019 (systematic review, 4 studies): oral and topical glutathione could brighten sun-exposed skin, but the evidence was inconclusive. Int J Dermatol 2024 (systematic review): five oral RCTs and one open study showed melanin-index reductions vs placebo; topical 0.5% outperformed 0.1% and placebo; combined topical and oral was better than either alone; only one placebo-controlled intravenous study (37.5% vs 18.7% responders, P=0.054); effects were moderate, localised or generalised, and unsustainable.
- Glutathione as a skin-lightening agent and in melasma: a systematic review (Int J Dermatol, 2024-10-23)
- The clinical effect of glutathione on skin color and other related skin conditions: a systematic review (J Cosmet Dermatol, 2019-06-01)
- Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study (J Dermatolog Treat, 2012-04-01)
Oral and topical forms were well tolerated in trials. A 2024 systematic review advises against intravenous glutathione for lightening because of lack of efficacy and side effects, and the CDC reported illnesses linked to contaminated compounded injections in 2026.
- Adverse events linked to compounded injectable glutathione: current situation (U.S. Centers for Disease Control and Prevention, 2026-09-11)
- Glutathione as a skin-lightening agent and in melasma: a systematic review (Int J Dermatol, 2024-10-23)
Long-term safety of oral use for lightening is not established, the effect appears not to last after stopping, and the quality of injectable products sold outside regulated pharmacies is uncertain.
- Glutathione as a skin-lightening agent and in melasma: a systematic review (Int J Dermatol, 2024-10-23)
- Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study (J Dermatolog Treat, 2012-04-01)
No drug dose is approved, and there is no approved injectable glutathione product in the US. Supplement amounts used in the studies are in the linked papers and are not a recommendation.
- Adverse events linked to compounded injectable glutathione: current situation (U.S. Centers for Disease Control and Prevention, 2026-09-11)
There is no approved drug label; supplement storage follows each product's packaging.
Glutathione itself is not named on the 2026 WADA Prohibited List. Separately, WADA prohibits intravenous infusions or injections of more than a total of 100 mL per 12-hour period (method M2.2), except those legitimately received in hospital treatment, surgery or clinical diagnostic investigations.
- WADA Prohibited List (World Anti-Doping Agency)
Egypt Peptides publishes reviewed scientific reference monographs for documentation and research. The site does not give individual medical advice, preparation or injection instructions, combination protocols or off-label use instructions. Decisions about any medicine belong to the treating physician.
- Glutathione as a skin-lightening agent and in melasma: a systematic review (Int J Dermatol, 2024-10-23)
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and published studiesAdverse events linked to compounded injectable glutathione: current situation ↗
https://www.cdc.gov/healthcare-associated-infections/current-situation/index.html
Glutathione as a skin-lightening agent and in melasma: a systematic review ↗
https://pubmed.ncbi.nlm.nih.gov/39444151/
The clinical effect of glutathione on skin color and other related skin conditions: a systematic review ↗
https://pubmed.ncbi.nlm.nih.gov/30895708/
Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study ↗
https://pubmed.ncbi.nlm.nih.gov/20524875/